Skip to content This is one of its most promising benefits. The glucagon receptor component is believed to help the liver burn stored fat more effectively, a mechanism not present in GLP-1-only or dual GIP/GLP-1 drugs like semaglutide and tirzepatide. Trials have shown meaningful improvement in liver fat content, which matters for conditions like MASLD (fatty liver disease)
